Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07734012) titled 'Mycophenolate After Stem Cell Transplant for Systemic Sclerosis' on July 24.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: None (Open Label).

Primary Sponsor: Ottawa Hospital Research Institute

Condition: Systemic Sclerosis (SSc)

Intervention: Drug: Mycophenolate Mofetil 1000 mg twice daily

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: August 2026

Target Sample Size: 6

Countries of Recruitment: Canada

To know more, visit https://clinicaltrials.gov/study/NCT07734012

Disclaimer...